Which one is better, Avatrombopag (Avatrombopag, Sucoxin) or Hatrimbopag?

Avatrombopag/Avatrombopag and Herombopag are drugs used to treat certain types of thrombocytopenia, especially in patients with chronic liver disease. Both drugs are thrombopoietin receptor agonists, which increase platelet levels by stimulating platelet production in the bone marrow. However, they have some differences in indications, pharmacokinetics, efficacy, and side effects.

Avatrombopag is commonly used to treat thrombocytopenia due to chronic liver disease, particularly in patients requiring invasive medical procedures. Its advantage is that it can significantly increase platelet counts in a short period of time, helping patients successfully undergo surgery or other medical interventions. Clinical studies have shown that avatrombopag is more effective in increasing platelet levels and can improve patients' quality of life to a certain extent.

Heltrombopag has a relatively wide range of indications. In addition to being used for thrombocytopenia in patients with chronic liver disease, it is also used to treat chronic immune thrombocytopenia (ITP). What is unique about this drug is its flexibility to target different patient groups, allowing it to meet the needs of more patients in practical applications. In addition, the administration of heltrombopag is relatively simple, usually orally, making it easier for patients to follow.

In terms of pharmacokinetics, avatrombopag has a short half-life, which means that its effects occur relatively quickly but may require more frequent dosing. Hatrombopag, on the other hand, has a longer half-life and may be more beneficial in maintaining effective platelet levels. However, the specific use of the drug still needs to be combined with the patient's actual situation. The doctor will make individualized adjustments based on the patient's condition, response to the drug, and possible side effects.

In terms of side effects, both may cause some common side effects, such as headache, nausea, diarrhea, etc., but the specific incidence and severity may vary depending on individual patients. In this regard, liver function abnormalities are relatively rare with avatrombopag, whereas heltrombopag has been shown in some studies to have some effect on liver function. Therefore, when selecting drugs, doctors need to comprehensively consider the patient's underlying disease, current medications, and potential risks.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC11228904/